Kidney transplantation in patients on anti‐tubercular therapy: A single centre observational study

• DOI: 10.1111/tid.14242
• Publication Date: 2024-01-25T09:49:04Z
• Authors: Pallavi Prasad; Sahil Bagai; Vandana Prasad; Rahul Grover; Gagandeep Chhabra; Dinesh Khullar
• Keywords: Male; Adult; Graft Rejection; Graft Survival; Antitubercular Agents; Middle Aged; Kidney Transplantation; Pyrazinamide; Young Adult; Treatment Outcome; 0302 clinical medicine; Humans; Tuberculosis; Kidney Failure, Chronic; Female; Rifampin; Ethambutol; Retrospective Studies

Abstract Background Tuberculosis (TB) is a common infection in chronic kidney disease. The prolonged therapy of TB can delay transplantation patients on antitubercular (ATT). Methods This was retrospective single‐center study to analyze the safety and its outcomes undergoing while continuation phase ATT. Results Between 2013 2022, 30 underwent Median age 38 years 70% were males. Majority (86.7%) had extrapulmonary tuberculosis, most site involvement being tubercular lymphadenitis. 14/30 microbiological/histopathological diagnosis rest diagnosed by ancillary tests. Patients treated with 4 drug ATT (isoniazid, rifampicin, pyrazinamide, ethambutol) before for aminimum 2 months. Post‐transplantation fluoroquinolone‐based non‐rifamycin used (median duration 11 months). All completed therapy. At years, there 100% patient survival 96.7% graft survival. eGFR at 6, 12, 24 months post‐transplantation 71.9, 64.7, 67 mL/min/1.73m , respectively. percentage suffering biopsy proven acute rejection 3.3%, 6.7%, 6.7%. Conclusion Kidney be done who have satisfactory response intensive decision should individualized. In our experience, excellent these low risk failure or relapse TB. image